Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 415 of the 415 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective of this document is to generate a practice guideline for the management and treatment of symptoms of the menopause. PARTICIPANTS: The Treatment of Symptoms of the Menopause Task Force included six experts, a methodologist, and a medical writer, all appointed by The Endocrine Society. EVIDENCE: The Task Force developed this evidenced-based guideline using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews of published data and considered several other existing meta-analyses and trials. CONSENSUS PROCESS: Multiple e-mail communications, conference calls, and one face-to-face meeting determined consensus. Committees of The Endocrine Society, representatives from endorsing societies, and members of The Endocrine Society reviewed and commented on the drafts of the guidelines. The Australasian Menopause Society, the British Menopause Society, European Menopause and Andropause Society, the European Society of Endocrinology, and the International Menopause Society (co-sponsors of the guideline) reviewed and commented on the draft. CONCLUSIONS: Menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and other symptoms of the climacteric. Benefits may exceed risks for the majority of symptomatic postmenopausal women who are under age 60 or under 10 years since the onset of menopause. Health care professionals should individualize therapy based on clinical factors and patient preference. They should screen women before initiating MHT for cardiovascular and breast cancer risk and recommend the most appropriate therapy depending on risk/benefit considerations. Current evidence does not justify the use of MHT to prevent coronary heart disease, breast cancer, or dementia. Other options are available for those with vasomotor symptoms who prefer not to use MHT or who have contraindications because these patients should not use MHT. Low-dose vaginal estrogen and ospemifene provide effective therapy for the genitourinary syndrome of menopause, and vaginal moisturizers and lubricants are available for those not choosing hormonal therapy. All postmenopausal women should embrace appropriate lifestyle measures.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a higher risk of breast cancer ( 162).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [162]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889 · cited 3×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
Background2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group, an international group with expertise in development and implementation of evidence-based guidelines (1).”
Method2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
(2004) · JAMA · doi:10.1001/jama.291.14.1701 · Cited by 4,534 · cited 2×
“(MPA) in women with a uterus (18), was associated with risks disproportionate to preventive benefits (17, 18).”
BackgroundClinician’s Guide to Prevention and Treatment of Osteoporosis
Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2794-2 · Cited by 4,149 · cited 2×
“Recent guidelines address bonespecific therapies (43).”
BackgroundWriting Group Members, Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N., Hailpern, S. M., Ho, M., Howard, V., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.187998 · Cited by 3,711
Breast cancer and hormone-replacement therapy in the Million Women Study
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14065-2 · Cited by 2,993
Systematic review and meta-analysis
(2019) · Providing Information for Health · doi:10.1201/9781315377315-19 · Cited by 2,659
Cited by
Items 401–500 of 883
Christelle, K., Zulkifli, M. M., Norhayati, M. N., & Draman, N. (2020) · Current Women s Health Reviews · doi:10.2174/1573404816999200702162750 · Cited by 8
Hormone therapy and fractures in postmenopausal women
Yin, M. T., Hoover, D. R., Shi, Q., Tien, P. C., Cohen, M. H., Kassaye, S. G., Gustafson, D., Adimora, A. A., Weitzmann, M. N., Bolívar, H., et al. (2022) · AIDS · doi:10.1097/qad.0000000000003292 · Cited by 6
Enhancing Care of the Survivor of Gynecologic Cancer: Managing the Menopause and Radiation Toxicity
Le, L. V., & McCormack, M. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158676 · Cited by 6
Kim, M., Kim, A., Park, H., Kwon, O., Kim, J., Park, E.-J., Baek, S.-E., Yoo, J., & Lee, J. (2018) · Trials · doi:10.1186/s13063-018-2443-8 · Cited by 6
“It is contraindicated in women with active liver disease, a history of breast or endometrial cancer, unexplained vaginal bleeding, coronary heart disease, or a history of venous thromboembolic events or stroke [6].”
BackgroundDeciphering the complex relationship between menopause and heart disease: 25 years and counting
Stuenkel, C. A. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001125 · Cited by 6
Self-citationFazekas, C., Linder, D., Matzer, F., Vajda, C., Avian, A., Theiler‐Schwetz, V., Trummer, C., Došen, J., Rokvic, J., Mohl, M., et al. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01809-y · Cited by 8
Yoshida, Y., Chen, Z., Baudier, R. L., Krousel-Wood, M. A., Anderson, A. H., Fonseca, V. A., & Mauvais‐Jarvis, F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.016 · Cited by 13
Bała, M. M., Sahebkar, A., Ursoniu, S., Șerban, M.-C., Undas, A., Mikhailidis, D. P., Lip, G. Y. H., Rysz, J., & Banach, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.024 · Cited by 6
Menopausal hormone therapy and breast cancer risk: effect modification by body mass through life
Sandvei, M. S., VATTEN, L. J., Bjelland, E. K., Eskild, A., Hofvind, S. S. H., Ursin, G., & Opdahl, S. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0431-7 · Cited by 8
Patterns of menopausal hormone therapy use and hyperkyphosis in older women
Woods, G. N., Huang, M.-H., Cawthon, P. M., McDaniels-Davidson, C. R., Fink, H. A., & Kado, D. M. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001070 · Cited by 6
“with bothersome vasomotor symptoms and no contraindications to treatment.(40) In 2017, the American College of Physicians Clinical Practice Guideline Update on Osteoporosis recommended against using menopausal estrogen or estrogen plus progesterone therapy for the treatment of osteoporosis in women.”
BackgroundEvidence for Postmenopausal Hormone Therapy to Prevent Chronic Conditions
Grady, D. G. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.7861 · Cited by 6
Premature Menopause and Risk for Cardiovascular Disease
Scarabin, P. Y. (2020) · JAMA · doi:10.1001/jama.2020.2533 · Cited by 6
Guo, Z.-Q. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1694240 · Cited by 11
Karam, J., SHUFELT, C. L., Safwan, N., Kapoor, E., Christmas, M., & Faubion, S. S. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002695 · Cited by 7
Roman, M.-P., Ciortea, R., Doumouchtsis, S. K., Din, R., Măluţan, A. M., Bucuri, C. E., Căşeriu, E.-A., Ormindean, C. M., Nati, I. D., Suciu, V.-E., et al. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.10.046 · Cited by 6
Lifelong Care of Females With Congenital Heart Disease
Tompkins, R. O., Venkatesh, P., Small, A. J., & Halpern, D. G. (2025) · Circulation Research · doi:10.1161/circresaha.124.325596 · Cited by 5
“98 There are no data on the safety of hormone replacement therapy in CHD, however, like contraception, estrogen remains a risk factor for thromboembolism.”
Mitoma, T., Ooba, H., Takahashi, K., Kondo, T., Ikeda, T., Sakamoto, Y., Mitsuhashi, T., & Maki, J. (2025) · Age and Ageing · doi:10.1093/ageing/afaf224 · Cited by 6
NAMS 2019 Pre-Meeting Symposium, September 2019, Chicago Illinois: The Perimenopause
Stuenkel, C. A., Santoro, N. F., Laughlin-Tommaso, S. K., Black, A., Joffe, H., & Su, H.-C. I. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001571 · Cited by 6
Self-citationSex Hormones and Their Impact on Cardiovascular Health
Jesus, S. D., Gianos, E., McNally, S. T., Scantlebury, D. C., & Rosen, S. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819369-3.00029-0 · Cited by 12
Concerns About Compounded Bioidentical Menopausal Hormone Therapy
Pinkerton, J. V. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000597 · Cited by 6
Self-citationMonteiro, M. R. P., Aragão-Santos, J. C., Vasconcelos, A. B. S., de Resende–Neto, A. G., Chaves, L. M. D. S., Pantoja-Cardoso, A., Nogueira, A. C., Carnero-Díaz, Á., Marcos-Pardo, P. J., Corrêa, C. B., et al. (2022) · Sports · doi:10.3390/sports10100143 · Cited by 7
“In particular, for the female public, this process is increased by menopause, characterized by the clinical status after the cessation of menses for 12 months, defining the final menstrual period [5].”
BackgroundLee, C., Han, K., Yoo, J., Park, K., & Oh, S. Y. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-05976-8 · Cited by 7
“Prescription of HRT to alleviate the vasomotor symptoms of menopause increased after FDA approval in 1988 [7, 8].”
BackgroundModern approach to the management of genitourinary syndrome in women with gynecological malignancies
Kovačević, N., Cilenšek, I., Merlo, S., & Šegedin, B. (2023) · Radiology and Oncology · doi:10.2478/raon-2023-0038 · Cited by 5
Inayama, Y., Mizuno, K., Egawa, M., Yamaguchi, K. D., Hamanishi, J., Takeuchi, M., Mandai, M., & Kawakami, K. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15795 · Cited by 8
Sexual experiences of postmenopausal women in China: a qualitative study
Chen, J., Zhai, H., Jin, H., Li, X., Zhang, P., & Chen, R. (2023) · Sexual Medicine · doi:10.1093/sexmed/qfad062 · Cited by 9
“MHT is the most effective treatment for the relief of bothersome symptoms associated with menopause, 38 while the rate of MHT use is approximately 2% in eligible Chinese women.”
BackgroundSalle, S. P., & Bourdeau, I. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae005 · Cited by 6
“Many of these symptoms remain unspecific and carry a large array of differential diagnosis, ranging from menopause to Cushing syndrome to other neuroendocrine tumors [12, 13].”
BackgroundHypertension in periand postmenopausal women: mechanisms, management, observation
Polyakova, E. A., Конради, А. О., Баранова, Е. И., Galyavich, A. S., Zhernakova, Y. V., Novikova, Т. N., Tapilskaya, N. I., Ткачева, О. Н., Ostroumova, O. D., Skibitsky, V. V., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5729 · Cited by 6
Cucinella, L., Tedeschi, S., Memoli, S., Cassani, C., Martini, E., & Nappi, R. E. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2416046 · Cited by 7
“Current recommendations recognize menopausal hormone therapy (MHT), namely, estrogen alone or in combination with progestogens in women with an intact uterus, as the most effective treatment for VMS [7–9].”
Rozenberg, S., & Vandromme, J. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.07.024 · Cited by 7
“This can be explained by the fact that many publications and guidelines, such as the Endocrine Society guidelines, suggest that MHT, when prescribed, should be initiated before the age of 60, or within the first 10 years of menopause [5].”
BackgroundUpdated treatment guideline for hormone therapy in postmenopausal women
Kwon, D. H., & Shin, J. (2019) · Journal of Korean Medical Association · doi:10.5124/jkma.2019.62.3.145 · Cited by 7
Management of Induced Menopause in Gynaecological Cancers and Their Challenges
Purohit, P., Sassarini, J., & Lumsden, M. A. (2019) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-019-0262-x · Cited by 5
Self-citationHormonersatztherapie und duktales Carcinoma in situ
Sourouni, M. (2019) · Journal für Gynäkologische Endokrinologie/Schweiz · doi:10.1007/s41975-019-00104-4 · Cited by 4
HTA et traitement hormonal de la menopause
Mounier‐Véhier, C., Bejan‐Angoulvant, T., Boivin, J., & Plu‐Bureau, G. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.09.027 · Cited by 6
Carcinoid syndrome and its sequelae
Ratnayake, G. M., & Toumpanakis, C. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.02.006 · Cited by 5
Cano, A., REES, M. C. P., & Simoncini, T. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.09.002 · Cited by 5
Time for Action: Managing Genitourinary Syndrome of Menopause
Williams, N. O., & Lustberg, M. B. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00350 · Cited by 5
“Use of vaginal estrogen is the gold standard treatment of GSM in postmenopausal women without a history of breast cancer.(3) However, this treatment is controversial in breast cancer survivors because of potential systemic absorption and the sensitivity of breast cancer to estrogen, particularly if hormone receptor po…”
BackgroundUnited States Menopausal Hormone Therapy Usage Trends
Faubion, S. S., Safwan, N., Saadedine, M., Hedges, M. S., Kling, J. M., Kapoor, E., Thao, V., Winham, S. J., Cole, K., Handley-Kelly, M. R., et al. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.021 · Cited by 5
Female Reproductive Endocrine Disorders
Selander-Han, M., McGee, S., & Lo, K. (2024) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2024.04.002 · Cited by 4
Youssef, E. A., Badie, M. S., Ismail, D., Gamal, A., & Eldamanhoury, H. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70011 · Cited by 4
Glynne, S., Kamal, A., Neville, A. M., McColl, L., Naji, O., Newson, L. R., & Reisel, D. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08161-w · Cited by 5
“…[12], and/or recommending a ‘proportionate’ increase in progestogen dose for all women using high doses of trans-dermal estradiol [1], is inconsistent with international menopause guidelines which recommend that MHT dose, formulation and route should be tailored to the individual [8, 9, 18].”
Karam, J., Paul, M. M., SHUFELT, C. L., Ravikumar, P., Fratianni, A. M., Oloyede, S. V., Pagel, E. M., Hedges, M. S., Kapoor, E., Kling, J. M., et al. (2025) · JMIR Research Protocols · doi:10.2196/76536 · Cited by 6
“The app’s educational and treatment content was developed using evidence-based guidelines on menopause symptom management from The Menopause Society, Endocrine Society, and American College of Obstetricians and Gynecologists [9,10,25,26].”
Sex Hormone Supplementation and Cardiovascular Disease Risk
Kampka, Z., Balwierz, M., & Wybraniec, M. T. (2026) · Medicina · doi:10.3390/medicina62010134 · Cited by 5
“Nowadays, HRT is not recommended for CVD prevention, neither by the American College of Obstetricians and Gynecologists nor the Endocrine Society [38,39].”
A Review of Alpha-2 Adrenergic Agents Implicated in Opioid Use Disorder
Hannum, A., Spano, I., & Ofori, E. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00970 · Cited by 6
Mapping menopause education for healthcare professionals: a scoping review
Keye, C., Murphy, M., Saab, M. M., & O’Driscoll, M. (2026) · Climacteric · doi:10.1080/13697137.2026.2676683 · Cited by 4
“…15% of UK women aged 45–64 years use HRt [25]. this under-use reflects multiple barriers, including product shortages [25], inequitable prescribing [26] and the lasting impact of the 2002 women’s Health initiative (wHi) trial, which continues to influence clinician and patient perceptions [27–29].”
MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence
Lukas, V. A., & Simon, J. A. (2020) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001516 · Cited by 4
Menopause: A primary care perspective
Ellington, K., Link, T., & Saccomano, S. J. (2022) · The Nurse Practitioner · doi:10.1097/01.npr.0000806384.48601.29 · Cited by 7
“VMS often last several years, but may persist for up to 10 years for postmenopausal women.(22) Onset of VMS earlier in the menopausal transition has been associated with longer duration of symptoms.”
BackgroundSafety and acceptability of intravaginal rings releasing estradiol and progesterone
Hull, M. L., Stuckey, B. G. A., Hartman, K., Zack, N., Thurman, A. R., & Friend, D. R. (2023) · Climacteric · doi:10.1080/13697137.2023.2194526 · Cited by 4
Turner, S., Allen, V. M., Graves, L. E., Tanguay, R. L., Green, C. R., & Cook, J. L. (2023) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2023.05.011 · Cited by 6
Treating obesity to optimize women’s health outcomes
Rubino, D., & Schon, S. B. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002595 · Cited by 4
The menopause specialist and breast cancer survivorship
Marsden, J. (2016) · Post Reproductive Health · doi:10.1177/2053369116668738 · Cited by 4
Reynolds, E. E., Bates, C. K., Richardson, M., & Burns, R. B. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3320 · Cited by 5
Computerized hybrid decision-making system for hormone replacement therapy in menopausal women
Bacak, H. O., Leblebicioğlu, K., Tanaçan, A., & Beksaç, M. S. (2018) · Technology and Health Care · doi:10.3233/thc-181235 · Cited by 6
“A second problem is the variety of clinical conditions that necessitates individual-based managements/treatments [12,16].”
Hormone replacement therapy: revisiting the risk of breast cancer
Franceschini, G., Lello, S., & Masetti, R. (2019) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000548 · Cited by 4
“These symptoms may include among others hot flushes, increased perspiration, genitourinary problems, bone demineralization, muscle-joint pain, changes in mood, sleep disturbances, changes in sexual function (Stuenkel et al., 2015; The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017).”
BackgroundEffects of Estrogens and SERMs on Bone Metabolism: Clinical Aspects
Clarke, B. L. (2020) · Contemporary Endocrinology · doi:10.1007/978-3-319-69287-6_12 · Cited by 7
Lv, S.-L., Wang, R., Xue, X., Zhao, L., Tuo, X., Ma, S., Liang, D., Wang, Y., Feng, X. M., Li, Q., et al. (2020) · Translational Cancer Research · doi:10.21037/tcr-19-3022a · Cited by 3
“The numerous acknowledged benefits of MHT have been widely recognized in the treatment of many immediate and delayed postmenopausal changes (4-6).”
BackgroundMenopause Hormone Therapy in the Management of Postmenopausal Osteoporosis
Rozenberg, S., Vandromme, J., Revercez, P., Valcarenghi, M., & Joris, A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000592 · Cited by 5
Costanian, C., Farah, R., Salameh, R., Meisner, B. A., Bahous, S. A., & Sibai, A. M. (2022) · Gerontology and Geriatric Medicine · doi:10.1177/23337214221138663 · Cited by 4
“Hormone therapy (HT) is indicated for women in the menopause transition to relieve vasomotor symptoms (Santen et al., 2010; Stuenkel et al., 2015).”
BackgroundVarlamov, E. V., & Fleseriu, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99899-4.00019-6 · Cited by 6
Hull, M. L., Stuckey, B. G. A., Hartman, K., Zack, N., & Friend, D. R. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002148 · Cited by 4
Price, S., Finch, S. J., Krejany, E. O., Jiang, H., Kale, A., Domchek, S. M., Wrede, C. D., Wark, J. D., & Hickey, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad385 · Cited by 6
Ovarian Insufficiency: Clinical Spectrum and Management Challenges
Stuenkel, C. A. (2024) · Journal of Women s Health · doi:10.1089/jwh.2023.0942 · Cited by 6
“25 Risks and benefits of HT. Assessment of individual benefits and risks is an important consideration when considering HT. 4,26,27 As no adequately powered randomized clinical trials (RCTs) of HT with clinical outcomes have been specifically conducted in younger, symptomatic postmenopausal women, the…”
InfluentialSelf-citationDon't be so quick to stop hormone-replacement therapy
Løbo, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.195 · Cited by 4
Pace, D. T. (2017) · The Nurse Practitioner · doi:10.1097/01.npr.0000526765.60971.37 · Cited by 4
“women.(20) Even though more than 18 years of data since the WHI have added to clinical knowledge of the risk/benefi t balance of prescribing hormones in the postmenopausal period, many women continue to be fearful of accepting a prescription for HT, and many clinicians remain confused by the changing evidence base.”
BackgroundÖzler, S., Bostancı, E. İ., Oztas, E., Pekcan, M. K., Güler, B. G., & Yılmaz, N. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0948-3 · Cited by 4
Park, J., Jung, Y. S., Kim, J. Y., Bae, S. H., & Jo, Y. (2019) · Asian Oncology Nursing · doi:10.5388/aon.2019.19.2.90 · Cited by 4
▼Ospemifene for vulvar and vaginal atrophy
(2019) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2019.000011 · Cited by 4
A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms
Cucinella, L., Cassani, C., Tedeschi, S., Memoli, S., Martini, E., & Nappi, R. E. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2495951 · Cited by 3
“Guidelines from many scientific menopause societies recommend MHT as the first-line for the treatment of moderate-to-severe VMS and that non-hormonal strategies should be offered when the woman shows contraindications or wishes to avoid hormonal treatments after adequate counseling [9–11].”
Zhang, W., Bao, H., Li, C., Zhai, Y., Liu, J., & Gong, J. (2025) · CHI Conference Extended Abstracts on Human Factors in Computing Systems (CHI EA) · doi:10.1145/3706599.3720129 · Cited by 5
Kumar, R., Rizvi, M. R., & Sami, W. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1524790 · Cited by 6
Hyaluronic acid and chondroitin sulphate instillation in chronic bladder diseases: a meta‐analysis
Corona, G., Capogrosso, P., Baldini, S., Rastrelli, G., Vignozzi, L., Otero, J., Salonia, A., Reisman, Y., Bettocchi, C., Maggi, M., et al. (2025) · British Journal of Urology · doi:10.1111/bju.70016 · Cited by 4
“These local changes can, in turn, favour the appearance of UTI and bladder in fl ammation, which represent key elements of the so-called genitourinary syndrome of menopause [71].”
Uçar, N., Shirvani, A., & Holick, M. F. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.09.006 · Cited by 6
“17 Whereas hormone replacement therapy can take several days to several weeks for some women to achieve its maximum bene fi t in controlling VMS, 7 KÜLKUF can induce almost immediately an effect that can be initiated every time the patient is beginning to experience the of a hot fl ash/hot fl…”
Nardin, S., Bruzzone, M., Arecco, L., Chiappe, E., Lanzavecchia, C., Ruelle, T., Giannubilo, I., Razeti, M. G., Borea, R., Barcellini, L., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116266 · Cited by 3
Bridging tradition and innovation: electroacupuncture’s impact on premature ovarian insufficiency
He, S., Ling, L., Sheng, Y., Zhao, X., Yuan, L. X., Liu, P., Li, B., & Zhang, B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1685306 · Cited by 4
Dong, J., Hillman, S., Dixon, S., Shah, A., Venkatakrishnan, R., & Tomlinson, J. (2026) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.70214 · Cited by 4
Cui, J., Hankinson, S. E., Matsumoto, A. M., Santen, R. J., Boutot, M. E., Budd, J. R., Dowsett, M., Goetz, M. P., Guranich, C., Houghton, S. C., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag188 · Cited by 3
Self-citationRimaz, S., Rahideh, S. T., Abolghasemi, J., Jazayeri, S., Jamshidi, S., Motevalian, M., Solaymani–Dodaran, M., Taghizadeh, M., Gholamrezayi, A., & Aryaeian, N. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002117 · Cited by 4
Zong, Y., Mao, T., Yao, P., Liang, J., Lai, Y., Chen, Z., Chen, S., Huang, L., Guo, Y., Zhu, M., et al. (2024) · Journal of Applied Microbiology · doi:10.1093/jambio/lxae016 · Cited by 5
Prevalencia y severidad de los síntomas de la menopausia en mujeres mayores de 60 años
Hoz, F. J. E. D. L. (2024) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.11.1.853 · Cited by 8
Menstruation: An Important Indicator for Assessing Stroke Risk and Its Outcomes
Seitz, A., & Raval, A. P. (2024) · Stroke · doi:10.1161/strokeaha.124.048869 · Cited by 7
“103,104 With respect to cardiovascular indications, phytoestrogen supplementation may modestly improve lipid profiles in postmenopausal women but may adversely affect carotid intima-media thickness.”
Review of current and emerging estrogen receptor agonists for vaginal atrophy
Donders, G. G. G., Akinosoglou, K., Massie, Z., & Özçelik, A. S. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2451150 · Cited by 3
“Despite these findings, the Endocrine Society Clinical Practice Guidelines do currently not recommend ospemifene for women with a history of breast cancer [41].”
Allam, A. R., Alhateem, M. S., & Mahmoud, A. M. (2025) · European journal of medical research · doi:10.1186/s40001-025-02279-y · Cited by 3
“However, safety and tolerability issues have deterred VMS patients from using HT [8, 11].”
Aesthetic Gynecology and Mental Health: What Does It Really Mean for Women?
Marano, G., Anesini, M. B., Sfratta, G., d’Abate, C., Traversi, G., Rossi, S., Lisci, F. M., Brisi, C., Paris, I., Pola, R., et al. (2025) · Cosmetics · doi:10.3390/cosmetics12010028 · Cited by 7
Li, X., Halaki, M., & Chow, C. M. (2025) · Sensors · doi:10.3390/s25103040 · Cited by 3
“Sleep disturbances affect around 40–60% of menopausal women [3,4].”
Pregnancy, Menopause, and Other Hormonal Factors
Combs, J. L., Netherton, E., & Combs, H. L. (2025) · Springer eBooks · doi:10.1007/978-3-031-87228-0_11 · Cited by 4
Prämature Ovarialinsuffizienz: ESHRE-Leitlinien und aktuelle Studien
Feil, K., Zippl, A. L., & Tóth, B. (2019) · Journal für Gynäkologische Endokrinologie/Österreich · doi:10.1007/s41974-019-0103-y · Cited by 4
Hormone replacement therapy following treatment of gynaecological malignancies
Richardson, A., Ayres, J., Cust, M., & Phillips, A. (2019) · The Obstetrician & Gynaecologist · doi:10.1111/tog.12607 · Cited by 3
Mehta, J. M., & Kling, J. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-44459-4_14 · Cited by 3
Ménopause et risque thromboembolique veineux. RPC Les femmes ménopausées du CNGOF et du GEMVi
Hugon‐Rodin, J., Pérol, S., & Plu‐Bureau, G. (2021) · Gynécologie Obstétrique Fertilité & Sénologie · doi:10.1016/j.gofs.2021.03.018 · Cited by 6
Efficacy of non-hormonal therapy for menopausal syndrome treatment
Yarmolinskaya, M. I., Tatarova, N. A., Kasyan, V. N., & Petrosyan, A. (2021) · Russian Bulletin of Obstetrician-Gynecologist · doi:10.17116/rosakush20212102191 · Cited by 3
Marian, I. R., Goff, M., Williams, J. A. E., Gulati, M., Chester‐Jones, M., Francis, A., Watson, M., Vincent, T. L., Woollacott, S., Mackworth-Young, C. G., et al. (2021) · Pilot and Feasibility Studies · doi:10.1186/s40814-021-00869-1 · Cited by 4
Cvetkovic, A., King, E. M., Skerritt, L., Loutfy, M. R., Tseng, A. L.-I., Murray, M. C. M., van Schalkwyk, J., Boucoiran, I., Marcotte, S., Hankins, C. A., et al. (2021) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2021-0014 · Cited by 8
Santoro, N. F., Coons, H. L., Khoudary, S. R. E., Epperson, C. N., Holt-Lunstad, J., Joffe, H., Lindsey, S. H., Marlatt, K. L., Montella, P., Richard-Davis, G., et al. (2022) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001995 · Cited by 3
Self-citationCorrales, E. P., Castro, M. A., Ortiz-Flores, A. E., & Escobar-Morreale, H. F. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.004 · Cited by 3
Multidisciplinary Management of Menopause: Symposium Proceedings
Kornstein, S. G., Pinkerton, J. V., Pace, D. T., Singer, A. J., Kingsberg, S. A., Ellis, L. E., Ashley, P., & Klein, W. (2022) · Journal of Women s Health · doi:10.1089/jwh.2022.0175 · Cited by 3
“29 32 Next, Pace discussed GSM, also known as VVA.”
Self-citationReduced macrophage killing of M. avium drives infection risk in post-menopausal patients
Weathered, C., Wei, N., & Pienaar, E. (2023) · Tuberculosis · doi:10.1016/j.tube.2023.102304 · Cited by 5
Cetera, G. E., Merli, C. E. M., Boero, V., Caia, C., & Vercellini, P. (2023) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2023.06.025 · Cited by 4
Approche pragmatique à la prise en charge de la ménopause
Lega, I. C., Fine, A., Lam-Antoniades, M., & Jacobson, M. R. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221438-f · Cited by 4
Piñeros, Y. S. S., Deckers, M. M. L., de Bie, P., Heijboer, A. C., & Hillebrand, J. J. (2024) · Endocrine Connections · doi:10.1530/ec-24-0432 · Cited by 3
“In the absence of clinical information on the menstrual cycle, the criteria for the postmenopausal state in women were set at age >50 years and serum follicle-stimulating hormone (FSH) >30 U/L (measured using Alinity (Abbott Diagnostics) or Cobas e601 (Roche Diagnostics)) ( 13, 14).”
Pinkerton, J. V. (2024) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002474 · Cited by 3
Self-citationWang, L., Xiao, Y., Luo, M., & Huang, R. (2025) · Climacteric · doi:10.1080/13697137.2025.2470450 · Cited by 4
Metadata
- Authors
- Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-11
- Volume
- 100
- Issue
- 11
- Pages
- 3975-4011
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2162957019
- Cited by
- 884
- References
- 414
- Citations by year
- 2026: 79 · 2025: 96 · 2024: 66 · 2023: 69 · 2022: 82 · 2021: 96 · 2020: 121 · 2019: 89 · 2018: 75 · 2017: 57 · 2016: 47 · 2015: 4
- FWCI
- 52.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- menopause, hormone replacement therapy, vasomotor symptoms, climacteric, postmenopausal women, cardiovascular risk screening, breast cancer risk, ospemifene, vaginal estrogen, genitourinary syndrome of menopause, vaginal moisturizers, lifestyle intervention, personalized treatment
- MeSH terms
- Contraindications, Age Factors, Breast Neoplasms, Cardiovascular Diseases, Female, Humans, Menopause, Terminology as Topic, Risk Factors, Severity of Illness Index, Estrogen Replacement Therapy, Evidence-Based Medicine, Hot Flashes, Female Urogenital Diseases, Venous Thromboembolism, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.